Literature DB >> 26564730

Intramedullary fixation in severe Charcot osteo-neuroarthropathy with foot deformity results in adequate correction without loss of correction - Results from a multi-centre study.

Martinus Richter1, Thomas Mittlmeier2, Stefan Rammelt3, Per-Henrik Agren4, Sarah Hahn5, Anica Eschler2.   

Abstract

BACKGROUND: Charcot osteo-neuroarthropathy (CN) of the foot can induce severe instability and deformity. Results of a consecutive clinical multi-centre study with Midfoot Fusion Bolt (MFB, Synthes GmbH, Oberdorf, Switzerland) are reported.
METHODS: All patients (aged 18 years and older) treated between 2009 and 2013 with surgical reconstruction of the midfoot with MFB for CN were included. Demographics, pre-surgical health status, details of foot pathology, details of surgery, postoperative treatment, treatment failure, and adverse events were registered. The following radiographic angles were measured on pre-op, post-op and last follow-up radiographs: talo-1st metatarsal (TMT) angle dorsoplantar and lateral view, and calcaneo-5th metatarsal angle.
RESULTS: Forty-seven patients (48 feet) were included in three centres. In 38 patients (80.1%) diabetes was diagnosed. Wound healing problems occurred in 21% of patients and recurrent ulceration in 13%. Revision surgery for loss of correction was performed in three cases (6%). Union rate at final follow-up was 98%. Major amputation for deep infection was performed in two patients (4%), minor amputation at the foot level in three cases (6%). Failure was more frequent when only one MFB (instead of 2 or 3) was used and no Gastrocnemius lengthening was performed. Radiographic alignment significantly improved pre- versus postoperatively and preoperatively versus follow-up.
CONCLUSIONS: Realignment and fixation with MFB in severe CN result in adequate correction with minimal loss of correction in the observed clinical course. The non-union rate was lower than previously reported. Stable fixation with MFB is a valuable treatment option for CN with minimal loss of correction and high union rates. The use of a minimum of two bolts is recommended to avoid recurrent deformity. Clinical Trials.gov: NCT01770639.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Charcot arthropathy; Correction; Deformity; Intramedullary fixation

Mesh:

Year:  2015        PMID: 26564730     DOI: 10.1016/j.fas.2015.02.003

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.705


  5 in total

1.  High rate of complications after corrective midfoot/subtalar arthrodesis and Achilles tendon lengthening in Charcot arthropathy type Sanders 2 and 3.

Authors:  Markus Regauer; Veronika Grasegger; Julian Fürmetz; Adrian Calvacanti Kussmaul; Wolfgang Böcker; Christian Ehrnthaller
Journal:  Int Orthop       Date:  2022-09-22       Impact factor: 3.479

2.  Charcot foot reconstruction outcomes: A systematic review.

Authors:  Joon Ha; Thomas Hester; Robert Foley; Ines L H Reichert; Prashanth R J Vas; Raju Ahluwalia; Venu Kavarthapu
Journal:  J Clin Orthop Trauma       Date:  2020-04-20

3.  Biomechanical investigation of two plating systems for medial column fusion in foot.

Authors:  Paul Simons; Theresia Sommerer; Ivan Zderic; Dieter Wahl; Mark Lenz; Hristo Skulev; Matthias Knobe; Boyko Gueorguiev; R Geoff Richards; Kajetan Klos
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

4.  Corneal Subbasal Nerve Plexus Changes in Severe Diabetic Charcot Foot Deformity: A Pilot Study in Search for a DNOAP Biomarker.

Authors:  Anica Herlyn; Ruby Kala Prakasam; Sabine Peschel; Stephan Allgeier; Bernd Köhler; Karsten Winter; Rudolf F Guthoff; Thomas Mittlmeier; Oliver Stachs
Journal:  J Diabetes Res       Date:  2018-11-04       Impact factor: 4.011

5.  Surgical treatment of midfoot charcot neuroarthropathy review of literature and our results after superconstruct reconstruction of midfoot charcot neuroarthropathy.

Authors:  Johnny Frøkjær
Journal:  J Clin Orthop Trauma       Date:  2021-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.